A safe and highly efficient tumor-targeted type I interferon immunotherapy depends on the tumor microenvironment

Despite approval for the treatment of various malignancies, clinical application of cytokines such as type I interferon (IFN) is severely impeded by their systemic toxicity. AcTakines (Activity-on-Target cytokines) are optimized immunocytokines that, when injected in mice, only reveal their activity...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncoimmunology
Autors principals: Cauwels, Anje, Van Lint, Sandra, Garcin, Geneviève, Bultinck, Jennyfer, Paul, Franciane, Gerlo, Sarah, Van der Heyden, José, Bordat, Yann, Catteeuw, Dominiek, De Cauwer, Lode, Rogge, Elke, Verhee, Annick, Uzé, Gilles, Tavernier, Jan
Format: Artigo
Idioma:Inglês
Publicat: Taylor & Francis 2017
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5790344/
https://ncbi.nlm.nih.gov/pubmed/29399401
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2017.1398876
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars